US BioDefense forms bioengineered skin deal
This article was originally published in Clinica
US BioDefense, a Department of Defense central contractor, has signed an option licence agreement with a major university to evaluate an adult stem cell sorting and enrichment technology that could be applied to gene therapy and bioengineered skin technology, which is a $1bn market.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.